Loading
A phase 1/2 trial of AZD3470, Pembrolizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. is a phase 1/2 interventional study registered as NCT06137144 by AstraZeneca, with 161 participants planned, started 2024-01-23 and due to reach its primary completion in 2029-05-03. Interventions recorded: AZD3470, Pembrolizumab. Conditions listed: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL). No results are recorded here; the registry entry is the source.